Although targeting both IL-17 and IFN-γ appeared promising in pre-clinical studies (Buonocore et al., 2010), neutralizing these cytokines or blockade of IL-17R failed to demonstrate clinical efficacy against Crohn’s disease (Hueber et al., 2012; Kaser, 2014). Here, IL17A is linked to Crohn disease.